medRxiv preprint doi: https://doi.org/10.1101/2022.12.26.22283911; this version posted December 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

### Exome sequencing reveals aggregates of rare variants in glycosyltransferase and 1 other genes influencing immunoglobulin G and transferrin glycosylation 2

- 3
- Arianna Landini<sup>1,2</sup>, Paul R.H.J. Timmers<sup>1,2</sup>, Azra Frkatović-Hodžić<sup>3</sup>, Irena Trbojević-4 Akmačić<sup>3</sup>, Frano Vučković<sup>3</sup>, Tea Pribić, Regeneron Genetics Center<sup>4</sup>, Gannie Tzoneva<sup>4</sup>, Alan 5 R. Shuldiner<sup>4</sup>, Ozren Polašek<sup>5,6</sup>, Caroline Hayward<sup>1</sup>, Gordan Lauc<sup>3,7</sup>, James F. Wilson<sup>\*1,2</sup> & 6
- Lucija Klarić\*1 7
- 8 1 MRC Human Genetics Unit, Institute for Genetics and Cancer, University of Edinburgh,
- 9 Edinburgh, United Kingdom
- 2 Centre for Global Health Research, Usher Institute, University of Edinburgh, Edinburgh, 10
- 11 United Kingdom
- 12 3 Genos Glycoscience Research Laboratory, Zagreb, Croatia
- 4 Regeneron Genetics Center, Tarrytown, NY, USA 13
- 14 5 Department of Public Health, School of Medicine, University of Split, Split, Croatia
- 15 6 Algebra University College, Zagreb, Croatia
- 16 7 Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
- 17
- \* Authors contributed equally. 18
- 19 Correspondence to: J.F.W (jim.wilson@ed.ac.uk) or L.K. (lucija.klaric@ed.ac.uk)
- 20

### 21 Abstract

22 It is often difficult to be certain which genes underlie the effects seen in association studies. However, variants that disrupt the protein, such as predicted loss of function (pLoF) and 23 24 missense variants, provide a shortcut to identify genes with a clear biological link to the 25 interest. Glycosylation is one the phenotype of of most common post-26 translationalmodifications of proteins, and an important biomarker of both disease and its 27 progression. Here, we utilised the power of genetic isolates, gene-based aggregation tests and 28 intermediate phenotypes to assess the effect of rare (MAF<5%) pLoF and missense variants 29 from whole exome sequencing on the N-glycome of plasma transferrin (N=1907) and immunoglobulin G (N=4912), and their effect on diseases. We identified significant gene-30 31 based associations for transferrin glycosylation at 5 genes (p<8.06x10<sup>-8</sup>) and for IgG glycan traits at 4 genes ( $p<1.19\times10^{-7}$ ). Associations in three of these genes (FUT8, MGAT3 and 32 RFXAP) are driven by multiple rare variants simultaneously contributing to protein 33 glycosylation. Association at ST6GAL1, with a 300-fold up-drifted variant in the Orkney 34 35 Islands, was detectable by a single-point exome-wide association analysis. Glycome-associated 36 aggregate associations are located in genes already known to have a biological link to protein 37 NOTECTIVISATEDIM (FIGIFGeVilleFBellionat nanodergeineerilleFB, pA4GeAiFBanathoSiEGG Velused on Sleegilibert passien

- genes which have not been previously reported (e.g. RFXAP for IgG). To assess the potential 38
- 39 impact of rare variants associated with glycosylation on other traits, we queried public
- 40 repositories of gene-based tests, discovering a potential connection between transferrin
- glycosylation, *MSR1*, galectin-3, insulin-like growth factor 1 and diabetes. However, the exact 41
- mechanism behind these connections requires further elucidation. 42

### 43 Introduction

Genome-wide association studies (GWAS) have so far identified thousands of loci associated 44 with human complex traits and diseases. However, the large majority of these variants are 45 found in noncoding regions of the genome<sup>1</sup>, posing a challenge when attempting to uncover 46 47 their functional impact on the phenotype. On the contrary, whole-exome sequencing (WES) studies offer the opportunity to identify rare variants of larger effect on the encoded protein. 48 49 such as predicted loss of function (pLoF) and missense variants, for which causal biological 50 mechanisms are generally easier to elucidate<sup>2</sup>. Methods for exome-wide rare variant analysis 51 have been successfully employed to discover variants and genes associated with both complex molecular traits<sup>3</sup> and diseases<sup>4,5</sup>. While single-variant tests, such as GWAS, are largely adopted 52 to explore associations of common genetic variants with phenotypes of interest, they have little 53 power to identify rare variant associations, due to the low number of observations. Therefore, 54 55 a set of methods testing cumulative effects of multiple rare variants in genetic regions, where rare variants are grouped at the gene level (also known as 'masks') via a collapsing test, such 56 57 as burden tests, or variance-component tests (e.g. sequence kernel association test, SKAT<sup>6</sup>) were developed. In addition to increasing the statistical power by aggregating multiple rare-58 variants, using genetically isolated populations can provide unique opportunities for novel 59 60 discovery in an association study<sup>7</sup>. Recent bottlenecks, restricted immigration and limited 61 population size lead to increased genetic drift. Consequently, in such populations some 62 otherwise rare variants can substantially increase in frequency compared to the general 63 population, therefore increasing association power for these variants.

64 Glycosylation is one of the most frequent post-translational modifications, where sugar residues, called glycans, are attached to the surface of proteins. Changes in protein N-65 glycosylation patterns have been described in the ageing process<sup>8,9</sup> and in a wide variety of 66 complex diseases, including autoimmune diseases<sup>10</sup>, diabetes<sup>11</sup>, cardiovascular diseases<sup>12</sup>, 67 neurodegenerative diseases<sup>13</sup> and cancer<sup>14</sup>. Despite glycans having an important role in human 68 health and serving as potential biomarkers in clinical prognosis and diagnosis<sup>15</sup>, we have just 69 started scratching the surface of the complex network of genes regulating protein glycosylation. 70 71 All studies published to date exploring the genetic regulation of total plasma protein, 72 immunoglobulin G (IgG) and transferrin N-glycosylation have employed single variant-based 73 GWAS tests, mostly uncovering common variants located in non-coding regions of the genome<sup>16–23</sup>. Rare variants contributing to glycan variation, and their impact on human health, 74 75 thus remain unexplored.

To address this knowledge gap, we used multiple gene-based aggregation tests to investigate 76 how rare (MAF<5%) pLoF and missense variants from whole exome sequencing affect 51 77 transferrin (N = 1907) and 94 IgG (N = 4912) glycan traits in European-descent cohorts. IgG 78 79 is both the most abundant antibody and one of the most abundant proteins in human serum. It 80 contains evolutionary conserved N-glycosylation sites in the constant region of each of its heavy chains, occupied by biantennary, largely core-fucosylated and partially truncated glycan 81 structures, that may carry a bisecting N-acetylglucosamine and sialic acid residues<sup>24,25</sup>. 82 83 Transferrin is a blood plasma glycoprotein that binds iron (Fe) and consequently mediates its

transport through blood plasma. Human transferrin has two N-glycosylation sites, with
biantennary disialylated digalactosylated glycan structure without fucose being the most
abundant glycan attached<sup>26,27</sup>.

In this study, we used gene-based aggregation of rare variants to identify several genes associated with transferrin and IgG glycosylation traits. Significant genes include known protein glycosylation genes as well as novel genes with no previously known role in posttranslational modification. Importantly, several associations would not have been detectable by single-point analysis and one association was detected thanks to enrichment of rare variants in population isolates. Finally, we highlight the impact of rare variation in these genes on healthrelated traits by performing gene-based aggregation tests of 116 health-related traits together

94 with gene lookups in public repositories of gene-based association tests

### 95 **Results**

### 96 **Exome variant annotation**

97 To assess the effect of rare genetic variants on glycosylation of two proteins, we sequenced the 98 exomes of 4.801 participants of European ancestry. After quality control, a total of 233.820 99 distinct autosomal coding genetic variants were available in the ORCADES cohort (N=2090), 244,649 in the VIKING cohort (N=2106) and 340,203 in the CROATIA-Korcula cohort 100 (N=2872). Percentages of variants for each effect category in the total sequenced coding 101 102 variation are similar across the three cohorts (Table 1). More than half (~53%) of the sequenced coding variants are missense variants, of which nearly half (~28% of total coding variation) are 103 classified as likely or possibly deleterious by multiple variant effect predictor algorithms (see 104 Methods). The second most represented effect category is synonymous mutations (~33%), 105 106 followed by variants in splice regions (~8%), predicted loss of function (pLoF) (~4%) and inframe insertions/deletions (~1.5%). Around one guarter of coding variants in the ORCADES 107 108 and VIKING cohorts are singletons (minor allele count, MAC=1); this percentage is instead

higher in CROATIA-Korcula cohort (~35%), possibly due to the larger sequenced sample size. 109

### Table 1. Number of coding exome variants sequenced in the complete sample of 3 isolated 110

111 cohorts. Counts and prevalence of autosomal variants observed in WES-targeted regions

across all individuals in the ORCADES, CROATIA-Korcula and VIKING cohort, by type or 112 functional class for all and for singleton variants (MAC=1). 113

|                               |          |          |          | CRC      | )ATIA-Ko | orcula   |                        |          |          |  |
|-------------------------------|----------|----------|----------|----------|----------|----------|------------------------|----------|----------|--|
|                               | ORC      | ADES (N= | =2090)   |          | (N=2872) | )        | <b>VIKING (N=2106)</b> |          |          |  |
|                               |          | % of     |          |          | % of     |          |                        | % of     |          |  |
|                               |          | total    | Variants |          | total    | Variants |                        | total    | Variants |  |
| Variant                       | No. of   | coding   | % with   | No. of   | coding   | % with   | No. of                 | coding   | % with   |  |
| category                      | variants | variants | MAC=1    | variants | variants | MAC=1    | variants               | variants | MAC=1    |  |
| coding variants               | 233,820  |          | 25.1%    | 340,203  |          | 35.5%    | 244,649                |          | 28.9%    |  |
| pLOF                          | 8639     | 3.69%    | 37.1%    | 12,970   | 3.81%    | 47.2%    | 9025                   | 3.69%    | 41.4%    |  |
| Splice acceptor               | 872      | 0.37%    | 37.8%    | 1309     | 0.38%    | 45.5%    | 945                    | 0.39%    | 42.7%    |  |
| Splice donor                  | 1042     | 0.45%    | 37.5%    | 1506     | 0.44%    | 48.1%    | 1079                   | 0.44%    | 40.4%    |  |
| Stop gained                   | 2833     | 1.21%    | 36.8%    | 4171     | 1.23%    | 47%      | 2879                   | 1.18%    | 41.8%    |  |
| Frameshift                    | 3401     | 1.45%    | 37.8%    | 5274     | 1.55%    | 47.9%    | 3583                   | 1.46%    | 42.1%    |  |
| Stop lost                     | 151      | 0.06%    | 32.5%    | 244      | 0.07%    | 43%      | 182                    | 0.07%    | 39%      |  |
| Start lost                    | 340      | 0.15%    | 30%      | 466      | 0.14%    | 44.2%    | 357                    | 0.15%    | 30.3%    |  |
| Missense                      | 124,416  | 53.2%    | 27%      | 183,056  | 53.8%    | 37.6%    | 130,299                | 53.3%    | 30.6%    |  |
| Likely benign (0-<br>1)       | 56,366   | 24.1%    | 21.8%    | 80,777   | 23.7%    | 31.6%    | 59,141                 | 24.2%    | 25.4%    |  |
| Possibly<br>deleterious (2-3) | 31,693   | 13.5%    | 28.1%    | 47,235   | 13.9%    | 39.1%    | 33,138                 | 13.5%    | 31.6%    |  |

| Likely<br>deleterious (4-5) | 35,728 | 15.3% | 34.2% | 54,187  | 15.9% | 45.4% | 37,384 | 15.3% | 38.2% |
|-----------------------------|--------|-------|-------|---------|-------|-------|--------|-------|-------|
| Unclassified missense       | 629    | 0.27% | 23%   | 857     | 0.25% | 29.3% | 636    | 0.26% | 23.1% |
| Splice region               | 18,580 | 7.95% | 24.7% | 26660   | 7.84% | 32.4% | 19,297 | 7.89% | 27.8% |
| In-frame indel              | 3383   | 1.45% | 21.5% | 5244    | 1.54% | 29.5% | 3606   | 1.47% | 26%   |
| Protein altering            | 3      | 0%    | 33.3% | 4       | 0%    | 25%   | 2      | 0%    | 0%    |
| Stop retained               | 1      | 0%    | 0%    | 2       | 0%    | 50%   | 1      | 0%    | 25.2% |
| Synonymous                  | 78,798 | 33.7% | 21.1% | 112,267 | 33%   | 31.6% | 82,419 | 33.7% | 100%  |

114

## 115 Exome-wide aggregated rare variant analysis of transferrin and IgG glycomes

116 We performed exome-wide gene-based tests across 51 transferrin traits (glycome subset of CROATIA-Korcula N = 948, VIKING N = 959) and 94 IgG glycan traits (glycome subset of 117 ORCADES N = 1960, CROATIA-Korcula N = 1866, VIKING N = 1086), testing low 118 119 frequency and rare (MAF <5%) pLoF and missense variants. In total, we identified 16 significant associations for transferrin- (Supplementary Table 1) and 32 significant associations 120 121 for IgG- (Supplementary table 2) glycan traits, at Bonferroni-corrected p-values of 8.06x10<sup>-8</sup> 122 and 1.19x10<sup>-7</sup>, respectively (Figure 1, Table 2). Most gene-aggregated rare variants were 123 associated with protein-specific glycans (transferrin: variants in FUT6, TIRAP, MSR1 and 124 FOXI1 genes, IgG: variants in MGAT3, ST6GAL1 and RFXAP genes); only FUT8 was 125 associated with glycans from both proteins (Table 2, Supplementary Tables 1 and 2). Almost all identified genes encode key enzymes in protein glycosylation (MGAT3, ST6GAL1, FUT6, 126 FUT8) or have been previously associated with transferrin and IgG glycan traits in GWAS 127 analysis (*MSR1*, *FOXI1*)<sup>17,18</sup>. The exceptions are *TIRAP* and *RFXAP*, which have no previously 128 known link to protein glycosylation. We successfully replicated (p-value  $< 3.2 \times 10^{-4}$  for 129 transferrin, p-value  $< 5.9 \times 10^{-4}$  for IgG) associations of glycans with low-frequency and rare 130 variants from 4 genes - FUT6 and TIRAP with transferrin glycans, and FUT8 and MGAT3 for 131 132 IgG glycans (Table 2) - as frequencies of variants in these genes are similar across the studied 133 cohorts (Supplementary Table 3). While the associations of IgG glycans and variants from FUT8 replicated, the association of transferrin glycans with variants from the same gene did 134 not reach the significance threshold for replication (p-value in VIKING =  $1.7 \times 10^{-3}$ ), likely 135 because of the 7-fold decreased frequency of the rs2229678 variant in the VIKING (MAF = 136 137 (0.0056) compared to CROATIA-Korcula (MAF = 0.049) cohort (Supplementary Table 4). 138 However, given the known biological role of FUT8 in protein glycosylation as a fucosyltransferase (one of the enzymes involved in the synthesis of glycans), we believe this 139 140 association to be real. Associations of rare variants from the CROATIA-Korcula cohort in the MSR1 gene with transferrin glycosylation also did not formally replicate in the VIKING cohort 141 142  $(p-value = 8.6x10^{-4})$  (Table 2). However, the cumulative allele count of rare variants in this gene is different between CROATIA-Korcula (MAC=46) and the VIKING cohort (MAC=38) 143 144 (Supplementary Table 3), decreasing the power to replicate. We also detected a couple of

145 isolate-specific associations that are driven by variants increased in frequency compared to publicly accessible biobanks and variant repositories. Namely, the rs750567016 variant in 146 ST6GAL1 that affects IgG glycosylation is more than 300 times more common in ORCADES 147  $(MAF = 3.3x10^{-3})$  than in UK Biobank  $(MAF = 1.0x10^{-5})$  or gnomAD  $(MAF = 9.0x10^{-6})$  and 148 is absent from CROATIA-Korcula and VIKING cohorts. The rs115399307 variant in FOXII. 149 150 associated with transferrin glycosylation, is seven times more common in VIKING (MAF = 2.1x10<sup>-2</sup>) than in CROATIA-Korcula cohort (MAF =  $2.7x10^{-3}$ ), UK Biobank (MAF =  $8.5x10^{-3}$ ) 151 <sup>3</sup>) and gnomAD (MAF =  $7.1 \times 10^{-3}$ ) (Supplementary Table 4). While the role of sialyltransferase 152 ST6GAL1 in IgG glycosylation is well described, the roles of the transcription factor FOXI1 153 and the regulatory factor X-associated protein RFXAP still need to be confirmed and 154 155 investigated.



156

Figure 1. Miami plot summarising the results from exome-wide gene-based tests for 157 transferrin and IgG glycan traits. Genomic positions of the genes, calculated as the mean 158 position of variants included in the reported mask, are labelled on the x-axis and the  $-\log_{10}$  of 159 the p-value for each rare-variants aggregating test on the y-axis. For each gene-glycan 160 161 association, the lowest p-value across multiple masks, multiple variant aggregate tests and 162 cohorts was selected for plotting. The Bonferroni-corrected significance threshold for 163 transferrin glycan traits (horizontal red line in the top part of the plot) corresponds to 8.06x10<sup>-</sup> <sup>8</sup>, while Bonferroni-corrected threshold for the IgG glycan traits (horizontal red line in the 164 bottom part of the plot) corresponds to 1.19x10<sup>-7</sup>. Genes significantly associated with 165 transferrin/IgG glycan traits are indicated with a triangle and labelled, while genes not passing 166 167 the significance threshold are indicated with dots.

# 168 Table 2: Gene-based rare variants associations of transferrin and IgG glycosylation.

| Lead glycan                 | Gene    | MAF    | Variants                          | N<br>variants | Discovery<br>cohort | Discovery<br>P         | Assoc.<br>test | Discovery<br>MAF | Discovery<br>AC | Repl.<br>cohort     | Repl. P                | Repl.<br>MAF | Repl.<br>AC | No. of<br>glycans |
|-----------------------------|---------|--------|-----------------------------------|---------------|---------------------|------------------------|----------------|------------------|-----------------|---------------------|------------------------|--------------|-------------|-------------------|
| Transferrin                 |         |        |                                   |               |                     |                        |                |                  |                 |                     |                        |              |             |                   |
| TfGP20                      | FUT8    | <0.05  | pLoF and<br>deleterious<br>(1/5)* | 6             | CROATIA-<br>Korcula | 6.29x10 <sup>-20</sup> | Burden         | 0.0111           | 124             | VIKING              | 1.73x10 <sup>-3</sup>  | 0.0042       | 8           | 3                 |
| TfGP32                      | FUT6    | < 0.05 | pLoF and<br>deleterious<br>(1/5)* | 5             | CROATIA-<br>Korcula | 4.31x10 <sup>-18</sup> | SKAT           | 0.0097           | 90              | VIKING              | 1.56x10 <sup>-14</sup> | 0.0072       | 96          | 8                 |
| TfGP35                      | MSR1    | < 0.05 | pLoF                              | 3             | CROATIA-<br>Korcula | 6.93x10 <sup>-17</sup> | Burden         | 0.0083           | 46              | VIKING              | 8.64x10 <sup>-4</sup>  | 0.01         | 38          | 2                 |
| TfGP17                      | TIRAP   | < 0.05 | pLoF and<br>deleterious<br>(1/5)* | 3             | VIKING              | 2.17x10 <sup>-10</sup> | SKAT-O         | 0.0077           | 44              | CROATIA-<br>Korcula | 8.12x10 <sup>-9</sup>  | 0.0076       | 98          | 2                 |
| TfGP23                      | FOXII   | <0.05  | pLoF and missense                 | 3             | VIKING              | 1.37x10 <sup>-8</sup>  | SKAT-O         | 0.0074           | 42              | CROATIA-<br>Korcula | 1.56x10 <sup>-2</sup>  | 0.0014       | 8           | 1                 |
| IgG                         |         |        |                                   |               |                     |                        |                |                  |                 |                     |                        |              |             |                   |
| FG2S1/<br>(FG2+FG2S1+FG2S2) | ST6GAL1 | <0.01  | pLoF and missense                 | 2             | ORCADES             | 9.82x10 <sup>-22</sup> | Burden         | 0.0019           | 15              | -                   | -                      | -            | -           | 9                 |
| Fn/(Bn+FBn)                 | MGAT3   | <0.01  | pLoF and<br>deleterious<br>(1/5)* | 4             | ORCADES             | 2.31x10 <sup>-10</sup> | SMMAT-<br>E    | 0.0021           | 33              | CROATIA-<br>Korcula | 6.57x10 <sup>-9</sup>  | 0.0012       | 29          | 17                |
| FG1n total/G1n              | FUT8    | <0.05  | pLoF and missense                 | 7             | CROATIA-<br>Korcula | 6.74x10 <sup>-8</sup>  | Burden         | 0.0072           | 177             | ORCADES             | 3.04x10 <sup>-6</sup>  | 0.0037       | 43          | 5                 |

| GP21  | RFXAP   | <0.01    | pLoF and missense | 2            | ORCADES         | 1.04x10 <sup>-7</sup> | SMMAT-<br>E   | 0.0033         | 26             | VIKING           | 6.29x10 <sup>-2</sup> | 0.0009      | 2           | 1          |
|---|---|----------|-------------------|--------------|-----------------|-----------------------|---------------|----------------|----------------|------------------|-----------------------|-------------|-------------|------------|
| Lead glycan - glycan trait reporting the strongest rare-variants association at the gene. Gene – gene for which rare variants are grouped. MAF - the highest allele frequency of variants aggregated for                      |   |          |                   |              |                 |                       |               |                |                |                  |                       |             |             |            |
| the mask. Variants - fun  | ctional cons  | equence  | of variants in th | e mask, ag   | gregated in the | given gene            | (pLoF – pred  | licted loss of | function: * c  | lenotes the nur  | nber of algori        | thms predi  | cting the   | missense   |
| variant to be deleterious)  | ). N variants   | - numbe  | r of variants inc | luded in the | mask. Discove   | ery cohort - c        | ohort reporti | ng the lower   | p-value for th | e glycan-gene    | association. D        | iscovery/H  | Repl. P - j | o-value of |
| the gene-based association  | on with the l   | ead glyc | an trait in the d | iscovery/rep | lication cohor  | t. Assoc. test        | - gene-based  | d association  | test for which | h p-value is rej | ported. Discov        | ery/repl. N | /IAF - me   | ean minor  |
| allele frequency of variation   | allele frequency of variants from the mask in the discovery/replication cohort. Discovery/repl. AC - sum of allele counts of variants from the mask in the discovery/replication cohort. Repl. Cohort - |          |                   |              |                 |                       |               |                |                |                  |                       |             |             |            |
| cohort reporting the higher p-value for the glycan-gene association. No. of glycans - number of other glycan traits associated with variants from the same mask. Results for transferri glycome are                           |   |          |                   |              |                 |                       |               |                |                |                  |                       |             |             |            |
| reported at the top of the table, while results for IgG glycome are reported at the bottom of the table. Discovery significance threshold is 8.06x10 <sup>-8</sup> for transferrin and 1.19x10 <sup>-7</sup> for IgG glycans. |   |          |                   |              |                 |                       |               |                |                |                  |                       |             |             |            |
| eplication significance threshold is 3.23x10 <sup>-4</sup> for transferrin and 5.95x10 <sup>-4</sup> for IgG glycans.   |   |          |                   |              |                 |                       |               |                |                |                  |                       |             |             |            |

### 170 IgG glycans gene-based aggregation meta-analysis

To further increase statistical power, we performed gene-based aggregation meta-analysis of 171 IgG glycan traits for ORCADES and VIKING cohorts. In addition to two genes already found 172 to be associated with IgG in the cohort-specific analysis (MGAT3 and ST6GAL1), the combined 173 analysis of VIKING and ORCADES cohort added FUT6 to the list of genes whose rare variants 174 are significantly (p-value<1.19x10<sup>-7</sup>) associated with IgG glycan traits (Supplementary Table 175 5). FUT6 is another gene known to be involved in glycosylation<sup>17,20,22,23</sup>, encoding a 176 glycosyltransferase enzyme that catalyses the transfer of fucose moieties to a growing glycan 177 178 chain.

179

### 180 Genetic architecture of aggregated effects of rare-variants

To better understand the genetic architecture of identified associations, we next assessed 181 182 whether our findings could be discoverable within a GWAS framework and whether they are driven by single variants or multiple rare variants working in concert to affect levels of 183 transferrin/IgG glycosylation. 184

We first performed GWAS on imputed genotypes for each glycan trait and then repeated the 185 186 rare variant association tests incorporating the dosages of GWAS sentinel SNPs as additional covariates. Genome-wide significant (transferrin p-value<1.61x10<sup>-9</sup>, IgG p-value<2.38x10<sup>-9</sup>) 187 associations reported in this study (Supplementary Table 6 for transferrin glycans and 188 Supplementary Table 7 for IgG glycans) have been described in further details in Landini et 189 al.<sup>18</sup> and Klarić et al.<sup>17</sup>. Overall, aggregated associations with variants from 3 out of 8 genes, 190 *FUT8*, *ST6GAL1* and *MGAT3*, remained significant (p-value <8.06x10<sup>-8</sup> for transferrin and p-191 value<1.19x10<sup>-7</sup> for IgG) after conditioning on sentinel GWAS associations (Table 3). For one 192 193 gene, RFXAP, there were no significant associations in the GWAS analysis, while the remaining four gene-based associations (FUT6, MSR1, FOXI1 and TIRAP) were explained by 194 sentinel GWAS variants. For two of these genes, FUT6 and FOXII, the GWAS sentinel 195 variants are low frequency (0.02<MAF<0.05; Supplementary Table 8). More specifically, for 196 transferrin glycans, 14 out of the 16 glycome-gene aggregate pairs fail to reach genome-wide 197 significance (p-value <8.06x10<sup>-8</sup>) after conditioning on GWAS sentinel SNPs (Supplementary 198 199 Table 9), meaning that a considerable part of the rare variant signal was dependent on variants 200 identifiable by GWAS. In contrast, for IgG glycans, 24 of the 32 glycome-gene aggregate pairs 201 remained significant (p-value $<1.19 \times 10^{-7}$ ), even after adjusting for GWAS sentinel SNPs 202 (Supplementary Table 10).

203 Next, we performed single-point exome-wide association analysis (ExWAS) and repeated the aggregated rare variant association tests while conditioning on the sentinel ExWAS 204 associations. In this way we tested whether the rare-variants associations with glycosylation 205 were driven by a single variant (i.e. showed an attenuated signal after conditioning on the 206 207 sentinel ExWAS variant) or were actually affected by multiple rare variants in concert (i.e. associations remain significant after the conditioning). Two of the associations, between 208

209 variants in the FUT8 gene and IgG glycans, and variants in the MGAT3 gene and transferrin

- glycans, remain significant after conditioning on the sentinel ExWAS variant (Table 3). Upon 210
- 211 closer inspection, for both of these genes, the sentinel ExWAS variant was a common variant
- that is also an eQTL for the gene in blood (eQTLGen<sup>28</sup>: rs35949016, FUT8 eQTL, p-value = 212
- $6.5 \times 10^{-159}$ ; rs6001566, MGAT3 eOTL p-value =  $3.9 \times 10^{-230}$ ) (Supplementary Table 8). Hence, 213
- it appears that glycosylation is affected by common variants and independently by aggregates 214 215 of rare variants in these two genes. Indeed, by looking at the single-point effects of each rare
- variant from the mask, we can see that multiple independent rare variants contribute to the 216
- 217 effect on glycosylation levels (Supplementary Table 11).
- 218 In summary, four of the identified associations, three with low-frequency variants from FUT6,
- 219 MSR1 and FOXI1 and one with a common variant from the TIRAP gene, could have been
- 220 discovered using a GWAS of imputed genotype data. On the other hand, the rare variant
- 221 association at ST6GAL1 gene could only have been discovered using an ExWAS, as it is too
- 222 rare to be imputed well. Finally, associations with variants from two genes, FUT8 and MGAT3,
- are driven by multiple rare variants simultaneously contributing to glycosylation of IgG and 223
- 224 transferrin. Also the rare variant association at *RFXAP* gene could not have been discovered
- 225 by either GWAS or ExWAS as there were no significant single-point associations. However,
- it is important to note that we could not replicate this association because the variants from its 226
- mask are depleted in the other studied cohorts (Supplementary Table 4). 227

228 Table 3: Genetic architecture of aggregated effect of rare variant associations when conditioning on sentinel variants from GWAS or

ExWAS analysis. Two associations, those with variants from the *FUT8* and *MGAT3* regions remain significant after conditioning on
 GWAS/ExWAS sentinel variants. Associations with variants from the *MSR1* gene are dependent on both GWAS and ExWAS sentinel variants.

231 The association with variants from the *ST6GAL1* gene is driven by the sentinel ExWAS variant, which was not present in the imputed GWAS.

| Lead glycan                 | Gene                | MAF                 | Variants                          | Association test       | cohort              | Discovery P            | GWAS adj p               | ExWAS adj p              |
|-----------------------------|---------------------|---------------------|-----------------------------------|------------------------|---------------------|------------------------|--------------------------|--------------------------|
| Transferrin                 |                     |                     |                                   |                        |                     |                        |                          |                          |
| TfGP20                      | FUT8                | < 0.05              | pLoF and<br>deleterious<br>(1/5)* | Burden                 | CROATIA-<br>Korcula | 6.29x10 <sup>-20</sup> | 2.75x10 <sup>-12</sup>   | 2.70 x10 <sup>-15</sup>  |
| TfGP32                      | FUT6                | < 0.05              | pLoF and<br>deleterious<br>(1/5)* | SKAT                   | CROATIA-<br>Korcula | 4.31x10 <sup>-18</sup> | 3.07x10 <sup>-1</sup>    | 2.94 x10 <sup>-1</sup>   |
| TfGP35                      | MSR1                | < 0.05              | pLoF                              | Burden                 | CROATIA-<br>Korcula | 6.93x10 <sup>-17</sup> | 6.62x10 <sup>-7</sup>    | 3.70 x10 <sup>-3</sup>   |
| TfGP17                      | TIRAP               | <0.05               | pLoF and<br>deleterious<br>(1/5)* | SKAT-O                 | VIKING              | 2.17x10 <sup>-10</sup> | 8.61x10 <sup>-1</sup>    | 1.38 x10 <sup>-1</sup>   |
| TfGP23                      | FOXI1               | < 0.05              | pLoF and missense                 | SKAT-O                 | VIKING              | 1.37x10 <sup>-08</sup> | 6.85x10 <sup>-1</sup>    | 6.38 x10 <sup>-1</sup>   |
| IgG                         |                     |                     |                                   |                        |                     |                        |                          |                          |
| FG2S1/(FG2+F<br>G2S1+FG2S2) | ST6GAL1             | <0.01               | pLoF and missense                 | Burden                 | ORCADES             | 9.82x10 <sup>-22</sup> | 6.99x10 <sup>-19</sup>   | 1.44 x10 <sup>-2</sup>   |
| Fn/(Bn+FBn)                 | MGAT3               | <0.01               | pLoF and<br>deleterious<br>(1/5)* | SMMAT-E                | ORCADES             | 2.31x10 <sup>-10</sup> | 5.47x10 <sup>-10</sup>   | 5.68 x10 <sup>-10</sup>  |
| FG1n total/G1n              | FUT8                | < 0.05              | pLoF and missense                 | Burden                 | CROATIA-<br>Korcula | 6.74x10 <sup>-8</sup>  | 2.31x10 <sup>-6</sup>    | 8.4x10 <sup>-6</sup>     |
| GP21                        | RFXAP               | <0.01               | pLoF and missense                 | SMMAT-E                | ORCADES             | 1.04x10 <sup>-7</sup>  | 1.04x10 <sup>-7</sup> ** | 1.04x10 <sup>-7</sup> ** |
| Lead glycan - glyc          | can trait reporting | the strongest rare- | variants association at t         | he gene. Gene – gene f | or which rare vari  | ants are grouped. MA   | F - the highest allele   | frequency of variants    |

Lead glycan - glycan trait reporting the strongest rare-variants association at the gene. Gene – gene for which rare variants are grouped. MAF - the highest allele frequency of variants aggregated for the mask. Variants - functional consequence of variants in the mask, aggregated in the given gene (pLoF – predicted loss of function: \* denotes the number of algorithms predicting the missense variant to be deleterious). Association test – gene-based association test for which p-value is reported. Cohort - cohort reporting the lower p-value for the glycan-gene association. Discovery P - p-value of the gene-based association test with the lead glycan trait in the cohort. GWAS adj p – p-value of association test when conditioning on the significant variants from the GWAS analysis; \*\* no significant GWAS variants were found.. ExWAS adj p – p-value of association test when conditioning on

the significant variants from the ExWAS analysis; \*\* no significant ExWAS variants were found. Results for transferri glycome are reported at the top of the table, while results for IgG glycome are reported at the bottom of the table. P-value significance threshold is 8.06x10<sup>-8</sup> for transferrin and 1.19x10<sup>-7</sup> for IgG glycans.

### 233 Links to health-related traits

We next wanted to assess the potential impact of rare protein glycosylation variants on health. 234 Since some of the gene-glycan associations are population-specific, stemming from the genetic 235 drift in isolated populations, we first performed "gene-level PheWAS" with quantitative health-236 237 related traits measured in studied cohorts. At the same time, since these cohorts, because of their sample size, might be underpowered to detect associations with common diseases, we 238 queried public repositories of aggregated rare-variants associations for these genes. 239

We performed exome-wide "gene-level PheWAS" with 116 quantitative health-related traits 240 241 measured in the ORCADES, CROATIA-Korcula and VIKING cohorts, limited to the genes 242 containing pLoF and missense variants that were associated with transferrin or IgG glycome 243 variation (Table 2). When possible, we sought to perform the analysis in the same cohort where 244 the glycan-gene association was discovered. The only significant (p-value $< 5.4 \times 10^{-5}$ ) association was with transferrin glycosylation-associated rare variants from the MSR1 gene and 245 blood levels of HbA1c in the VIKING cohort (Supplementary Table 12). However, the 246 association with HbA1c levels is not significant in CROATIA-Korcula, the cohort where we 247 discovered the connection between MSR1 and transferrin glycosylation, and it also does not 248 replicate in ORCADES, suggesting that it might be a false positive association. We next 249 250 checked whether any of the glycome-associated genes were significantly associated with 251 health-related traits in UK Biobank. We used two repositories of aggregated rare-variants associations: Genebass<sup>29</sup> and the AstraZeneca PheWAS portal<sup>30</sup>. Missense variants from the 252 MSR1 gene were significantly associated with insulin-like growth factor 1 levels (IGF1) in 253 254 both Genebass (SKAT-O p-value =  $4.6 \times 10^{-10}$ ) and the PheWAS portal (p-value =  $1.6 \times 10^{-24}$ , for the "ptv5pcnt" collapsing model). 255

### 256 Discussion

Statistical power to detect associations with rare genetic variants can be increased by 257 aggregating the association signals across multiple rare variants in a gene<sup>31</sup>, or by using 258 genetically isolated populations where, due to genetic drift, some variants are increased in 259 frequency compared to a general population<sup>32</sup>. Further, intermediate phenotypes, more 260 proximal to the genes and consequently more strongly influenced by them, can be used as 261 "proxies' of complex diseases to boost power. Glycosylation, one of the most common post-262 263 translational modifications, is one such intermediate phenotype and has been implicated in many diseases<sup>10,13,14</sup>. Here, we utilised the power of genetic isolates, aggregation of multiple 264 rare variants and intermediate phenotypes to study the effect of rare variants on glycosylation 265 of two proteins and their effect on disease. 266

267 We performed multiple gene-based aggregation tests to assess associations with transferrin (N = 1907) and IgG (N = 4912) glycan traits in three isolated cohorts of European descent, testing 268 269 rare (MAF<5%) pLoF and missense variants from whole exome sequencing. We found rare 270 variants from 8 genes contributing to glycan levels of either IgG or transferrin. As previously 271 observed in GWAS using imputed genotypes, transferrin and IgG glycans showed mostly protein-specific gene-based associations<sup>18</sup>, including genes encoding known glycosylation 272 enzymes (transferrin - TIRAP, a gene in the proximity of ST3GAL4; IgG - ST6GAL1 and 273 274 MGAT3), transcription factors (transferrin - FOXI1), as well as other genes (transferrin - MSR1; IgG - RFXAP). On the other hand, rare variants in FUT8 and FUT6, genes encoding 275 276 fucosyltransferase enzymes adding core and antennary fucose structures to the synthesised 277 glycan, were associated with glycosylation of both proteins. Previously we showed that, while glycosylation of both transferrin and IgG proteins is associated with genes encoding FUT6 and 278 279 FUT8 fucosylation enzymes, these associations are driven by independent, protein-specific 280 variants mapped to the regulatory region of the two genes<sup>18</sup>. Accordingly, here we identified 281 rare variants in the exonic portions of FUT8 and FUT6, acting independently or in concert with 282 GWAS-identifiable variants.

283 We successfully replicated 4 gene-glycan associations (FUT6, FUT8, TIRAP and MGAT3); however, noting variants in certain genes were lower in frequency (MSR1 and FOXI1) or 284 completely absent (ST6GAL1 and RFXAP) in replication cohorts, we were underpowered to 285 286 replicate the glycan associations with the remaining four genes. Two of the 8 identified associations, the ones with variants from the FUT8 and MGAT3 genes, were driven by multiple 287 288 rare variants simultaneously contributing to protein glycosylation. The association with 289 variants from the ST6GAL1 gene would have been discovered using single-point ExWAS (but not GWAS). Interestingly, for all three of these genes, we have also detected common variants 290 independently affecting IgG and transferrin glycans. While four associations (TIRAP, FUT6, 291 292 MSR1 and FOXI1) could have been discovered using a GWAS of imputed genotype data, three 293 of them (*FUT6*, *MSR1* and *FOXI1*) were with low frequency variants (0.02 < MAF < 0.05). 294 The associations with the RFXAP gene could not have been discovered by either GWAS or 295 ExWAS single-point analysis.

Except for RFXAP and TIRAP, all of 8 identified genes have already been associated with IgG 297 and transferrin glycosylation in previous GWAS studies<sup>17,18,20,22,23</sup>. The novel gene *TIRAP* is 298 located in close proximity to ST3GAL4, another glycosyltransferase-coding gene known to be 299 associated with transferrin glycosylation. TIRAP has a function in the innate immune system. 300 where it is involved in cytokine secretion and the inflammatory response  $^{33,34}$ . The lead rare 301 302 variant in the mask, rs8177399 (Supplementary Table 3), in addition to being an expression 303 OTL (eOTL) for TIRAP and several other genes, is also a splicing OTL (sOTL) for ST3GAL4 in whole blood (GTEx<sup>35</sup>, p-value =  $1.9 \times 10^{-8}$ ). The regulatory factor X-associated protein 304 encoded by RFXAP gene, whose variants are associated with IgG glycans, is part of a 305 306 multimeric complex, called the RFX DNA-binding complex, that binds to certain major histocompatibility (MHC) class II gene promoters and activates their transcription. MHC-II 307 molecules are transmembrane proteins, found on the surface of professional antigen-presenting 308 cells (including B cells)<sup>36</sup>, which have a central role in development and control of the immune 309 310 response. While the mechanism of *TIRAP*'s influence on the glycome could be through 311 controlling the splicing of the known glycosyltransferase enzyme ST3GAL4, the precise role 312 of *RFXAP* in protein glycosylation still needs to be established.

Changes in the glycosylation patterns are often observed in a wide range of pathological states. 313

314 such as cancer, inflammatory, autoimmune, neurodegenerative and cardiovascular diseases<sup>37–</sup> 315 <sup>40</sup>. We thus assessed the potential involvement of glycome-associated genes in health, by performing, in the same three cohorts, gene-based association tests of 116 quantitative health-316 317 related traits, limited to genes whose rare variants we found associated with the protein 318 glycomes. However, given the likely small effect-size of variants on complex diseases, we did not find any significant associations. On the other hand, using publicly available repositories 319 320 of gene-based associations in the UK Biobank data, we found that rare missense variants from MSR1 (associated with transferrin glycosylation) were also associated with blood levels of 321 322 insulin-like growth factor 1 (IGF1). IGF1 is a hormone with significant structural and functional similarities to insulin: lower levels of IGF1 are associated with higher risk of Type 323 1 and 2 diabetes mellitus<sup>41,42</sup>. Recently, a rare deleterious missense variant in *IGF1* receptor 324 (*IGF1R*) was found to be significantly associated with Type 2 diabetes in UK Biobank, further 325 corroborating the link between IGF1 and diabetes<sup>43</sup>. In addition, genetic variants in *MSR1* have 326 327 been previously associated with plasma levels of the galectin-3-binding protein<sup>44</sup>. Similarly to IGF1, galectin-3 has been identified as a marker and a pathogenic factor in type 2 diabetes, 328 with the serum protein levels increased in type 2 diabetes patients<sup>47–51</sup>. An important part of 329 330 iron delivery depends on recycling transferrin via clathrin-mediated endocythosis. 331 Interestingly, binding of galectin-3 to transferrin can affect its intracellular trafficking<sup>45,46</sup>. Based on the glycosylation profile, galectin-3 was found bound only to a select, minor fraction 332 (~5%) of transferrin, while interestingly none or little was bound to  $IgG^{46}$ . Overall, variants 333 from the MSR1 gene seem to have a pleiotropic effect on transferrin glycosylation, galectin-3 334 335 and IGF1. In turn, both galectin-3 and IGF1 are associated with type 2 diabetes. The potential role of glycosylation of transferrin in these processes still needs to be established. 336

338 In conclusion, we identified rare pLoF and missense variants associated with transferrin and 339 IgG N-glycome, in both known and not previously reported genes (TIRAP, RFXAP). By 340 utilising the power of genetic isolates and aggregated effects of rare variants, we discovered biologically relevant associations with a 300-fold up-drifted variant in the ORCADES cohort 341 342 (in the sialyltransferase gene, ST6GAL1, affecting levels of sialylation of IgG) and associations 343 independent of single-point GWAS and ExWAS analyses (in glycosyltransferase genes FUT8 and MGAT3). Interestingly, many of glycan traits are influenced both by common and rare 344 345 variants, revealing a complex genetic architecture of these intermediate phenotypes. While we 346 did not find any robust links between glycome-associated genes and diseases in studied cohorts, we discover a potential link between transferrin glycosylation, galectin-3, IGF1 and diabetes. 347 The exact mechanism behind these connections still needs to be confirmed and further 348 349 explored. This study shows that, utilising the power of genetic isolates, gene-based aggregation tests and intermediate phenotypes such as glycosylation, rare variant associations are detectable 350 351 even in relatively small sample sizes (low thousands). However, larger cohorts would be required to identify the contribution of rare variants to multifactorial, complex diseases. 352

### 353 Methods

354

## 355 Genotypic data

### 356 Exome sequencing

The "Goldilocks" exome sequence data for ORCADES, CROATIA-Korcula and VIKING 357 cohorts was prepared at the Regeneron Genetics Center, following the protocol detailed in Van 358 Hout et al.<sup>2</sup> for the UK Biobank whole-exome sequencing project. In summary, the multiplexed 359 360 samples were sequenced on the Illumina NovaSeq 6000 platform using S2 flow cells. The raw sequencing data was processed by automated analysis using the DNAnexus platform<sup>52</sup>, where 361 files were converted to FASTO format, and then aligned to GRCh38 genome reference using 362 the BWA-mem<sup>53</sup>. Duplicated reads were identified and flagged by the Picard tool<sup>54</sup>. Genotypes 363 for each individual sample were called using the WeCall variant caller<sup>55</sup>. During quality 364 control, samples genetically identified as duplicates, showing disagreement between 365 366 genetically determined and reported sex, high rates of heterozygosity or contamination, low sequence coverage (less than 80% of targeted bases achieving 20X coverage) or discordant 367 368 with genotyping chip were excluded. The number of samples removed after quality control are listed in Supplementary Table 13 for each cohort. Finally, the "Goldilocks" dataset was 369 generated by (i) filtering out genotypes with read depth lower than 7 reads, (ii) keeping variants 370 371 having at least one heterozygous variant genotype with allele balance ratio greater than or equal 372 to 15% (AB  $\geq$  0.15) or at least one homozygous variant genotype, and (iii) filtering out variants 373 with more than 10% of missingness and HWE  $p < 10^{-6}$ . Overall, a total of 2,090 ORCADES (820 male and 1,270 female), 2,872 CROATIA-Korcula (1,065 male and 1,807 female) and 374 375 2,108 VIKING (843 male and 1,265 female) participants passed all exome sequence and genotype quality control thresholds. A pVCF file containing all samples passing quality control 376 377 was then created using the GLnexus joint genotyping tool.<sup>56</sup>

378

## 379 <u>Variant annotation</u>

Exome sequencing variants were annotated as described in Van Hout, et al.<sup>2</sup> In brief, each 380 variant was labelled with the most severe consequence across all protein-coding transcripts, 381 implemented using SnpEff<sup>57</sup>. Gene regions were defined according to Ensembl release 85. 382 Variants annotated as stop gained, start lost, splice donor, splice acceptor, stop lost and 383 frameshift were considered as predicted LOF variants. The deleteriousness of missense variants 384 385 was assessed using the following algorithms and classifications (based on dbNSFP 3.2): (1) SIFT: "D" (Damaging), (2) Polyphen2 HDIV: "D" (Damaging) or "P" (Possibly damaging), 386 (3) Polyphen2\_HVAR: "D" (Damaging) or "P" (Possibly damaging), (4) LRT<sup>58</sup>: "D" 387 (Deleterious) and (5) MutationTaster<sup>59</sup>: "A" (Disease causing automatic) or "D" (Disease 388 causing). Missense variants were considered "likely deleterious" if predicted as deleterious by 389

all five algorithms, "possibly deleterious" if predicted as deleterious by at least one of thealgorithms and "likely benign" if not predicted as deleterious by any of the algorithms.

392

## 393 <u>Generation of gene burden masks</u>

For each gene, we grouped the variants in the gene in four categories (masks), based on severity 394 of their functional consequence. Mask 1 included only predicted loss-of-function (pLoFs) 395 variants, mask 2 consisted of pLoF variants and all missense variants, and masks 3 and 4 396 contained pLoF and predicted deleterious missense variants ("possibly deleterious" and "likely 397 deleterious" for mask 3 and mask 4, respectively). We considered two separate variations of 398 each mask based on the frequency of the minor allele of the variants that were screened in that 399 400 group:  $MAF \le 5\%$  and  $MAF \le 1\%$ . Overall, up to 8 burden tests were performed for each gene 401 (Supplementary Table 14). Consequently, the masks are not independent - certain masks will include the variants listed in a different mask and additional, less severe or more frequent 402 403 variants.

404

## 405 Phenotypic data

## 406 Transferrin and IgG N-glycome quantification

407 Transferrin and total IgG N-glycome quantification for ORCADES, VIKING and CROATIA-Korcula samples was performed at Genos Glycobiology Laboratory, following the protocol 408 described in Trbojević-Akmačić et al.<sup>60</sup> for transferrin, in Pučić et al.<sup>61</sup> for IgG in ORCADES 409 cohort and batch 1 of CROATIA-Korcula cohort, in Trbojević-Akmačić et al.<sup>62</sup> for IgG in 410 411 VIKING cohort and batch 2 of CROATIA-Korcula cohort. In summary, proteins of interest 412 were first isolated from blood plasma (IgG depleted blood plasma, in the case of transferrin) using affinity chromatography binding to anti-transferrin antibodies plates for transferrin and 413 414 protein G plates for IgG. The protein isolation step was followed by release and labelling of N-415 glycans and clean-up procedure.. IgG N-glycans have been released from total IgG (all subclasses). N-glycans were then separated and quantified by hydrophilic interaction ultra-416 417 high-performance liquid chromatography (HILIC-UHPLC). As a result, transferrin and total 418 IgG samples were separated into 35 (transferrin: TfGP1 – TfGP35) and 24 (IgG: GP1 – GP24) 419 chromatographic peaks. It is worth noting that there is no correspondence structure-wise between transferrin TfGP and IgG GP traits labelled with the same number. 420

421

## 422 <u>Normalisation and batch correction</u>

Prior to genetic analysis, raw N-glycan UHPLC data was normalised and batch corrected to
reduce the experimental variation in measurements. Total area normalisation was performed
by dividing the area of each chromatographic peak (35 for transferrin, 24 for IgG) by the total

426 area of the corresponding chromatogram. Due to the multiplicative nature of measurement error

- 427 and right-skewness of glycan data, normalised glycan measurements were log10-transformed.
- Batch correction was then performed using the empirical Bayes approach implemented in the 428
- "ComBat" function of the "sva" R package<sup>63</sup>, modelling the technical source of variation (96-429
- 430 well plate number) as batch covariate. Batch corrected measurements were then exponentiated 431 back to the original scale. Prior to further analysis, each glycan trait was rank transformed to
- normal distribution using the "rntransform" function from the "GenABEL" R package<sup>64</sup>. 432
- 433

### Derived glycan traits 434

IgG derived traits analysed included those defined by Huffman et al.65, and were calculated 435 436 using the glycanr R package. In addition, new derived traits were calculated for both transferrin and IgG, representing the overall presence of a certain sugar structure on the totality of 437 transferrin/IgG N-glycan traits measured (e.g. percentage of fucosylation). These newly 438 439 generated traits are expected to give a direct insight in the biological pathway involved in the addition of the sugar moiety to glycan structures. Exact formulas used for defining transferrin 440 and IgG newly derived traits can be found in Supplementary Tables 15 and 16 respectively. 441

442

### 443 Health-related quantitative traits

To evaluate the potential effect of rare variants affecting glycome on health-related phenotypes. 444 445 in the same cohorts we collected 148 health-related, quantitative traits (e.g. anthropological 446 measurements, blood levels of proteins, metabolites and biomarkers). Excluding traits with fewer than 800 samples, a total of 116 traits were considered for analysis (75 traits for 447 448 ORCADES, 79 for VIKING and 47 for CROATIA-Korcula cohort). Each health-related trait was rank transformed to normal distribution using the "rntransform" function from the 449 "GenABEL" R package<sup>64</sup>, followed by applying the rare-variants association pipeline 450 451 described below.

452

### **Gene-based aggregation analysis** 453

We performed variant Set Mixed Model Association Tests (SMMAT)<sup>66</sup> on rank-transformed 454 glycan traits, fitting a GLMM adjusting for age, sex, sampling batch in the case of CROATIA-455 Korcula IgG glycan traits, and familial or cryptic relatedness by kinship matrix. The kinship 456 matrix was estimated from the genotyped data using the 'ibs' function from GenABEL R 457 package<sup>64</sup>. The SMMAT framework includes 4 variant aggregate tests: burden test, sequence 458 kernel association test (SKAT), SKAT-O and SMMAT-E, a hybrid test combining the burden 459 test and SKAT. The 4 variant aggregate tests were performed on 8 different pools of genetic 460 461 variants, called "masks", described above (Supplementary Table 14).

462 Discovery significance threshold was Bonferroni corrected for the approximate number of genes in the human genome, 20,000, and the number of independent glycan traits, 21 for IgG 463 and 31 for transferrin  $(0.05/20000/31 = 8.06 \times 10^{-8}$  for transferrin,  $0.05/20000/21 = 1.19 \times 10^{-7}$  for 464 IgG). The number of independent glycan traits was estimated as the number of principal 465 components that jointly explained 99% of the total variance of transferrin/IgG glycan traits in 466 467 each cohort (Supplementary Tables 17 and 18). PCA was calculated on rank-transformed glycan traits, separately for each cohort, using the "prcomp" function from "factoextra" R 468 package<sup>67</sup>. A gene association was considered significant if it passed the above-described 469 Bonferroni corrected significance threshold in at least one of the 4 performed variant aggregate 470 471 tests and if the cumulative allele count of the variants included in the gene was equal or higher than 10. Replication significance threshold was defined as P = 0.05 divided by the number of 472 genes and independent glycans to be replicated. For IgG glycans, this threshold was P =473  $5.95 \times 10^{-4}$  (P = 0.05/4 genes/21 glycans) and for transferrin glycans, this threshold was P = 474  $3.23 \times 10^{-4}$  (P = 0.05/5 genes/31 glycans). 475

A similar analysis plan was applied to the health-related phenotypes analysed. Variant Set 476 Mixed Model Association Tests (SMMAT)<sup>66</sup> was performed on rank-transformed traits, fitting 477 a GLMM adjusting for age, sex, first 20 ancestral principal components (PCs), batch covariates 478 479 when available (e.g. season, time of the day and batch/subcohort) and familial or cryptic 480 relatedness.

481

### 482 IgG glycome gene-based aggregation meta-analysis

Gene-based aggregation analysis of IgG glycan traits for ORCADES and VIKING cohorts was 483 repeated following the same approach as previously described, except for the restriction that 484 masks included only variants present in both cohorts. Since IgG GP3 was not quantified in 485 ORCADES cohort, this glycan was excluded from the meta-analysis, bringing the total number 486 of IgG glycan traits considered to 93. We then used the "SMMAT.meta" function of 487 "SMMAT" R package<sup>66</sup> to meta-analyse, for each trait, the two studies. To identify significant 488 489 results we filter results by the previously described Bonferroni-corrected significance threshold 490 of  $1.19 \times 10^{-7}$  and by the cumulative allele count of variants included in the gene equal or higher 491 than 10.

492

### 493 Genome-wide association analysis

494 Genome-wide association analyses (GWAS) between HRC-imputed genotypes and 51 transferrin N-glycan traits were performed in 948 samples from CROATIA-Korcula and 959 495 samples from VIKING. GWAS with 94 IgG N-glycan traits were performed in 1960 samples 496 from ORCADES, 1866 samples from CROATIA-Korcula and 1086 samples from VIKING. 497 498 The sample size of the same cohort differs between transferrin and IgG due to the different 499 number of samples successfully measured for glycosylation of each protein. Transferrin N-

500 glycan measurements were not available in ORCADES. Rank-transformed glycan traits were 501 adjusted for age and sex, as fixed effects, and relatedness (estimated as the kinship matrix calculated from genotyped data) as random effect in a linear mixed model, calculated using the 502 "polygenic" function from the "GenABEL" R package<sup>64</sup>. Since IgG N-glycan traits for the 503 504 CROATIA-Korcula cohort were measured at two separate occasions, the two were considered 505 as separate cohorts. Therefore, for CROATIA-Korcula, rank transformation was performed separately in each subcohort. Samples were then merged together for GWAS, but adding batch 506 507 (subcohort number - 1 or 2) as fixed effect covariate. Residuals of covariate and relatedness 508 correction were tested for association with Haplotype Reference Consortium (HRC) r1.1-509 imputed SNP dosages using the RegScan v. 0.5 software, applying an additive genetic model 510 of association.

511 The genomic control inflation factor ( $\lambda_{GC}$ ) was calculated for each glycan and health-related

512 trait. The mean genomic control inflation factor ( $\lambda_{GC}$ ) for IgG glycan traits was 1.002 (0.982-

513 1.026) in ORCADES, 1 in CROATIA-Korcula (0.971-1.031) and 0.993 in VIKING cohort

(0.972-1.017) cohort; for transferrin glycan traits  $\lambda_{GC}$  was 1.002 in CROATIA-Korcula (0.982-514

1.026) and 0.998 in VIKING (0.974-1.021) cohort. Overall, the confounding effects of the 515

- 516 family structure were correctly accounted for in our analyses.
- 517

### 518 Identification of rare variant associations independent of GWAS and ExWAS signals

To ensure that the rare variant associations identified were independent of associations with 519 520 variants discoverable by a GWAS or single-point exome-wide (ExWAS) analysis, we repeated the aggregate analysis while conditioning on the sentinel SNPs from the single-variant genome-521 522 wide or exome-wide analysis. First, we performed GWAS of glycan traits using the same individuals as in the analysis of the exome-sequencing data, but using as genotypes SNP 523 524 dosages imputed from the HRC imputation panel, as described above. For each glycan trait we defined the sentinel SNPs as the variants having the lowest significant p-value ( $p < 5x10^{-8}$ ) in 525 526 a 1Mb window, and MAF > 1%. Then we also performed the exome-wide association analysis 527 (ExWAS), following exactly the same protocol, but with exome sequencing data used for 528 genotypes. We then re-run variant aggregate analysis as previously described, but with adjusting the glycan traits for the genotype of the sentinel SNPs from the GWAS/ExWAS 529 530 significant loci, in addition to the other covariates listed above. The statistical significance level 531 was determined in the same way as outlined in the main analysis above.

532

### 533 Replication of glycome rare associations in different cohorts and associations with health-534 related traits

To investigate whether glycome rare-variants associations were cohort specific, each 535 536 significant gene-glycan trait pair from the cohort-level discovery analysis was tested for 537 associations in the remaining cohorts. The p-value threshold for replication was set to 3.23x10<sup>-</sup>

<sup>4</sup> for transferrin (0.05/31/5) and 5.95x10<sup>-4</sup> for IgG (0.05/21/4) glycans, correcting for the 538 539 number of independent glycan traits (i.e. 31 for transferrin and 21 for IgG) and the number of 540 discovered glycome-gene pairs (i.e. 5 for transferrin and 4 for IgG in gene-based aggregation 541 analysis).

542 To investigate whether the glycome associated rare-variants may also affect health-related phenotypes, we tested for association each glycome-associated gene and 116 health-related 543 traits The significance threshold was set to  $5.43 \times 10^{-5}$ , correcting for the number of health-544 related traits (116), and the number of discovered glycome-gene pairs and number of glycome-545 associated genes (8). 546

547

### 548 **Code availability**

We used publicly available software tools for all analyses. These software tools are listed in 549 550 the main text and in the Methods.

551

### 552 **Data availability**

553 There is neither Research Ethics Committee approval, nor consent from individual participants, 554 to permit open release of the individual level research data underlying this study. The datasets generated and analysed during the current study are therefore not publicly available. Instead, 555 the research data and/or DNA samples are available from accessQTL@ed.ac.uk on reasonable 556 557 request, following approval by the QTL Data Access Committee and in line with the consent 558 given by participants. Each approved project is subject to a data or materials transfer agreement (D/MTA) or commercial contract. The UK Biobank genotypic data used in this study were 559 560 approved under application 19655, 48511 and 19655 are available to qualified researchers via the UK Biobank data access process. The expression data used for the analyses described in 561 this manuscript were obtained from the GTEx Portal on 25/11/2022. Genebass 562 563 (https://app.genebass.org/) and AstraZeneca PheWAS portal (https://azphewas.com/) were accessed on 06/12/2022. 564

### 565 References

- Maurano, M. T. et al. Systematic localization of common disease-associated variation 566 1. 567 in regulatory DNA. Science (80-.). 337, 1190-1195 (2012).
- Van Hout, C. V et al. Exome sequencing and characterization of 49,960 individuals in 568 2. the UK Biobank. Nature 586, 749–756 (2020). 569
- 570 Bomba, L. et al. Whole-exome sequencing identifies rare genetic variants associated 3. 571 with human plasma metabolites. Am. J. Hum. Genet. (2022). 572 doi:10.1016/J.AJHG.2022.04.009
- 573 Flannick, J. et al. Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 4. 574 controls. Nature 570, 71–76 (2019).
- 575 Jurgens, S. J. et al. Analysis of rare genetic variation underlying cardiometabolic 5. 576 diseases and traits among 200,000 individuals in the UK Biobank. Nat. Genet. 2022 577 *543* **54**, 240–250 (2022).
- 578 6. Bansal, V., Libiger, O., Torkamani, A. & Schork, N. J. Statistical analysis strategies 579 for association studies involving rare variants. Nat Rev Genet 11, 773-785 (2010).
- 580 7. Zuk, O. et al. Searching for missing heritability: Designing rare variant association 581 studies. doi:10.1073/pnas.1322563111
- 582 8. Vanhooren, V. et al. Serum N-glycan profile shift during human ageing. Exp Gerontol 583 45, 738–743 (2010).
- 584 9. Vilaj, M., Gudelj, I., Trbojević-Akmačić, I., Lauc, G. & Pezer, M. IgG Glycans as a 585 Biomarker of Biological Age. in Biomarkers of Human Aging 81-99 doi:10.1007/978-586 3-030-24970-0 7
- 587 10. Ząbczyńska, M., Link-Lenczowski, P. & Pocheć, E. Glycosylation in Autoimmune 588 Diseases, in The Role of Glycosylation in Health and Disease (eds. Lauc, G. & 589 Trbojević-Akmačić, I.) 205–218 (Springer International Publishing, 2021). 590 doi:10.1007/978-3-030-70115-4 10
- 591 Rudman, N., Gornik, O. & Lauc, G. Altered N-glycosylation profiles as potential 11. 592 biomarkers and drug targets in diabetes. FEBS Letters 593, 1598–1615 (2019).
- 593 12. Gudelj, I. & Lauc, G. Protein N-Glycosylation in Cardiovascular Diseases and Related 594 Risk Factors. Curr. Cardiovasc. Risk Rep. 12, (2018).
- 595 Rebelo, A. L., Chevalier, M. T., Russo, L. & Pandit, A. Role and therapeutic 13. 596 implications of protein glycosylation in neuroinflammation. Trends Mol Med 28, 270-597 289 (2022).
- 598 14. Costa, A. F., Campos, D., Reis, C. A. & Gomes, C. Targeting Glycosylation: A New 599 Road for Cancer Drug Discovery. Trends Cancer 6, 757–766 (2020).
- 600 15. Peng, W. et al. Clinical application of quantitative glycomics. Expert Rev. Proteomics 601 15, 1007–1031 (2018).
- Huffman, J. E. et al. Polymorphisms in B3GAT1, SLC9A9 and MGAT5 are associated 602 16. 603 with variation within the human plasma N-glycome of 3533 European adults. Hum. 604 Mol. Genet. 20, 5000-5011 (2011).
- Klarić, L. et al. Glycosylation of immunoglobulin G is regulated by a large network of 605 17. 606 genes pleiotropic with inflammatory diseases. Sci. Adv. 6, eaax0301 (2020).
- 607 Landini, A. et al. Genetic regulation of post-translational modification of two distinct 18. 608 proteins. Nat. Commun. 2022 131 13, 1-13 (2022).
- Lauc, G. et al. Genomics Meets Glycomics-The First GWAS Study of Human N-609 19. 610 Glycome Identifies HNF1a as a Master Regulator of Plasma Protein Fucosylation. 611 PLoS Genet. 6, e1001256 (2010).
- Lauc, G. et al. Loci Associated with N-Glycosylation of Human Immunoglobulin G 612 20. 613 Show Pleiotropy with Autoimmune Diseases and Haematological Cancers. PLoS

| 614        |                | $C_{anat}$ <b>9</b> (2013)  |
|------------|----------------|---|
| 615        | 21             | Sharanov S. 7. at al. Defining the genetic control of human blood plasma N glycome                          |
| 616        | 21.            | using genome wide association study. Hum Mol. Canat. 28, 2062, 2077 (2010)                                  |
| 617        | $\gamma\gamma$ | Shen X at al Multivariate discovery and replication of five novel loci associated with                      |
| 619        | <i>LL</i> .    | Immunoglobulin G N glucocylation Nat. Commun <b>8</b> 447 (2017)  |
| 610        | 22             | Wahl A at al Conome wide essection study on immuneal chulin C alwaesulation                                 |
| 619        | 23.            | wani, A. <i>et al.</i> Genome-wide association study on minimunogrobulin G grycosylation                    |
| 020        | 24             | patterns. Front. Immunol. 9, 277 (2018).  |
| 622        | 24.            | Bondt, A. <i>et al.</i> Infinunoglobulin G (1gG) Fab grycosylation analysis using a new mass                |
| 622<br>623 |                | <i>Mol. Cell. proteomics</i> <b>13</b> , 3029–3039 (2014).  |
| 624        | 25.            | Wuhrer, M. et al. Glycosylation profiling of immunoglobulin G (IgG) subclasses from                         |
| 625        |                | human serum. Proteomics 7, 4070–4081 (2007).  |
| 626        | 26.            | Karlsson, I., Ndreu, L., Quaranta, A. & Thorsén, G. Glycosylation patterns of selected                      |
| 627        |                | proteins in individual serum and cerebrospinal fluid samples. J. Pharm. Biomed. Anal.                       |
| 628        |                | <b>145</b> , 431–439 (2017).  |
| 629        | 27.            | Spik, G. et al. Studies on glycoconjugates. LXIV. Complete structure of two                                 |
| 630        |                | carbohydrate units of human serotransferrin. FEBS Lett. 50, 296–299 (1975).                                 |
| 631        | 28.            | Võsa, U. <i>et al.</i> Large-scale cis- and trans-eQTL analyses identify thousands of genetic               |
| 632        |                | loci and polygenic scores that regulate blood gene expression. <i>Nat. Genet.</i> 2021 539                  |
| 633        |                | <b>53</b> . 1300–1310 (2021).   |
| 634        | 29.            | Karczewski, K. J. <i>et al.</i> Systematic single-variant and gene-based association testing of             |
| 635        |                | thousands of phenotypes in 394.841 UK Biobank exomes. <i>Cell Genomics</i> <b>2</b> .                       |
| 636        | 30.            | Wang, O. <i>et al.</i> Rare variant contribution to human disease in 281.104 UK Biobank                     |
| 637        |                | exomes. <i>Nature</i> <b>597</b> . 527–532 (2021).  |
| 638        | 31.            | Povvsil, G. <i>et al.</i> Rare-variant collapsing analyses for complex traits: guidelines and               |
| 639        |                | applications. <i>Nat. Rev. Genet.</i> <b>20</b> , 747–759 (2019).   |
| 640        | 32.            | Zuk, O. <i>et al.</i> Searching for missing heritability : Designing rare variant association               |
| 641        |                | studies. (2014). doi:10.1073/pnas.1322563111  |
| 642        | 33.            | Fitzgerald, K. A. <i>et al.</i> Mal (MvD88-adapter-like) is required for Toll-like receptor-4               |
| 643        | 001            | signal transduction. <i>Nature</i> <b>413</b> , 78–83 (2001).   |
| 644        | 34.            | Horng, T., Barton, G. M. & Medzhitov, R. TIRAP: an adapter molecule in the Toll                             |
| 645        | 0              | signaling pathway. <i>Nat Immunol</i> <b>2</b> , 835–841 (2001).  |
| 646        | 35.            | Aguet, F. <i>et al.</i> Genetic effects on gene expression across human tissues. <i>Nature</i> <b>550</b> . |
| 647        | 001            | 204–213 (2017)  |
| 648        | 36.            | Jones, E. Y., Fugger, L., Strominger, J. L. & Siebold, C. MHC class II proteins and                         |
| 649        | 001            | disease: a structural perspective. <i>Nat Rev Immunol</i> <b>6</b> , 271–282 (2006).                        |
| 650        | 37             | Iuszczak A <i>et al</i> Plasma fucosylated glycans and C-reactive protein as biomarkers of                  |
| 651        | 571            | HNF1A-MODY in young adult–onset nonautoimmune diabetes. <i>Diabetes Care</i> 42                             |
| 652        |                | 17–26 (2019)  |
| 653        | 38             | Pairo-Castineira E <i>et al</i> Genetic mechanisms of critical illness in COVID-19 <i>Nature</i>            |
| 654        | 50.            | <b>591</b> , 92–98 (2021).  |
| 655        | 39.            | Verhelst, X. et al. Protein Glycosylation as a Diagnostic and Prognostic Marker of                          |
| 656        |                | Chronic Inflammatory Gastrointestinal and Liver Diseases. <i>Gastroenterology</i> <b>158</b> , 95–          |
| 657        |                | 110 (2020).   |
| 658        | 40.            | Wittenbecher, C. et al. Plasma N-Glycans as Emerging Biomarkers of  |
| 659        |                | Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.                         |
| 660        |                | Diabetes Care 43, 661–668 (2020).   |
| 661        | 41.            | Meyer, N. M. T. et al. Low IGF1 and high IGFBP1 predict diabetes onset in                                   |
| 662        |                | prediabetic patients. Eur J Endocrinol 187, 555-565 (2022).   |
|            |                |   |

663 42. Segev, Y. et al. Systemic and renal growth hormone-IGF1 axis involvement in a

| 664 |     | mouse model of type 2 diabetes. <i>Diabetologia</i> <b>50</b> , 1327–1334 (2007).                               |
|-----|-----|---|
| 665 | 43. | Gardner, E. J. et al. Damaging missense variants in IGF1R implicate a role for IGF-1                            |
| 666 |     | resistance in the etiology of type 2 diabetes. Cell Genomics  |
| 667 |     | doi:10.1016/j.xgen.2022.100208  |
| 668 | 44. | Pietzner, M. et al. Genetic architecture of host proteins interacting with SARS-CoV-2.                          |
| 669 |     | bioRxiv Prepr. Serv. Biol. (2020). doi:10.1101/2020.07.01.182709  |
| 670 | 45. | Carlsson, M. C., Bengtson, P., Cucak, H. & Leffler, H. Galectin-3 guides intracellular                          |
| 671 |     | trafficking of some human serotransferrin glycoforms. J Biol Chem 288, 28398–28408                              |
| 672 |     | (2013).   |
| 673 | 46. | Cederfur, C. <i>et al.</i> Different affinity of galectins for human serum glycoproteins:                       |
| 674 |     | galectin-3 binds many protease inhibitors and acute phase proteins. <i>Glycobiology</i> 18.                     |
| 675 |     | 384–394 (2008).   |
| 676 | 47  | Atalar M N <i>et al</i> Assessment of serum galectin-3 methylated arginine and Hs-CRP                           |
| 677 | .,. | levels in type 2 diabetes and prediabetes <i>Life Sci</i> <b>231</b> 116577 (2019)                              |
| 678 | 48  | Lin D <i>et al.</i> Galectin-3/adiponectin as a new biological indicator for assessing the risk.                |
| 670 | 40. | of type 2 diabetes: a cross-sectional study in a community population A ging (Albany                            |
| 680 |     | NV) <b>13</b> 15/33 15/43 (2021)  |
| 601 | 40  | N1/13, 13435-13445 (2021).<br>Oblure T at al I are server galactin 2 concentrations are associated with inculin |
| 600 | 49. | variations in patients with type 2 disbates mallitus. Diabatel Matab Sundr 6, 106                               |
| 002 |     | (2014)  |
| 003 | 50  | (2014).<br>Nore A de Lemes I.A. Avens C. Credin I.I. & Linevey I. Association of                                |
| 684 | 50. | vora, A., de Lemos, J. A., Ayers, C., Grodin, J. L. & Lingvay, I. Association of                                |
| 685 |     | Galectin-3 with Diabetes Mellitus in the Dallas Heart Study. J Clin Endocrinol Metab                            |
| 686 |     | 104, 4449–4458 (2019).  |
| 687 | 51. | Weigert, J. <i>et al.</i> Serum galectin-3 is elevated in obesity and negatively correlates with                |
| 688 |     | glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 95, 1404–1411                               |
| 689 |     | (2010).   |
| 690 | 52. | Reid, J. G. <i>et al.</i> Launching genomics into the cloud: deployment of Mercury, a next                      |
| 691 |     | generation sequence analysis pipeline. BMC Bioinformatics 15, 30 (2014).  |
| 692 | 53. | Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler                                 |
| 693 |     | transform. <i>Bioinformatics</i> 25, 1754–1760 (2009).  |
| 694 | 54. | Institute, B. Picard Tools. (2018).   |
| 695 | 55. | PLC, G. weCall. (2018).   |
| 696 | 56. | Lin, M. F. et al. GLnexus: joint variant calling for large cohort sequencing. bioRxiv                           |
| 697 |     | (2018). doi:10.1101/343970  |
| 698 | 57. | Cingolani, P. et al. A program for annotating and predicting the effects of single                              |
| 699 |     | nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster                                 |
| 700 |     | strain w1118; iso-2; iso-3. Fly 6, 80–92 (2012).  |
| 701 | 58. | Chun, S. & Fay, J. C. Identification of deleterious mutations within three human                                |
| 702 |     | genomes. Genome Res 19, 1553–1561 (2009).   |
| 703 | 59. | Schwarz, J. M., Rodelsperger, C., Schuelke, M. & Seelow, D. MutationTaster                                      |
| 704 |     | evaluates disease-causing potential of sequence alterations. Nat Methods 7, 575–576                             |
| 705 |     | (2010).   |
| 706 | 60. | Trbojević-Akmačić, I. <i>et al.</i> Chromatographic monoliths for high-throughput                               |
| 707 |     | immunoaffinity isolation of transferrin from human plasma. Croat. Chem. Acta 89.                                |
| 708 |     | 203–211 (2016).   |
| 709 | 61. | Pucić, M. <i>et al.</i> High throughput isolation and glycosylation analysis of IgG-variability                 |
| 710 |     | and heritability of the IgG glycome in three isolated human populations. <i>Mol. Cell</i>                       |
| 711 |     | Proteomics 10. M111.010090-M111.010090 (2011).  |
| 712 | 62  | Trbojević Akmačić, L. Ugrina, I. & Lauc, G. Methods in Enzymology Volume 586.                                   |
| 713 |     | Chapter Three - Comparative Analysis and Validation of Different Steps in Glycomics                             |

- 714 Studies. (2017). doi:https://doi.org/10.1016/bs.mie.2016.09.027
- 715 63. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray
- 716 expression data using empirical Bayes methods. *Biostatistics* 8, 118–127 (2007).
- 717 Karssen, L. C., van Duijn, C. M. & Aulchenko, Y. S. The GenABEL Project for 64. 718 statistical genomics. F1000Research 5, 914 (2016).
- 719 Huffman, J. E. et al. Comparative Performance of Four Methods for High-throughput 65. 720 Glycosylation Analysis of Immunoglobulin G in Genetic and Epidemiological Research. Mol. Cell. Proteomics 13, 1598–1610 (2014). 721
- 722 Chen, H. et al. Efficient Variant Set Mixed Model Association Tests for Continuous 66. 723 and Binary Traits in Large-Scale Whole-Genome Sequencing Studies. Am J Hum 724 Genet 104, 260-274 (2019).
- 725 Kassambara, A. and Mundt, F. Factoextra: Extract and Visualize the Results of 67. 726 Multivariate Data Analyses. R Package Version 1.0.7. https://CRAN.R-727 project.org/package=factoextra (2020).

### 729 Acknowledgements

730

731 We thank Dr Nicola Pirastu for his help and advice regarding the statistical methods. The 732 Orkney Complex Disease Study (ORCADES) was supported by the Chief Scientist Office of 733 the Scottish Government (CZB/4/276 and CZB/4/710), the Royal Society, the MRC Human 734 Genetics Unit, Arthritis Research UK and the European Union framework program 6 735 EUROSPAN project (contract number LSHG-CT-2006-018947). ORCADES DNA 736 extractions and genotyping were performed at the Genetics Core of the Clinical Research Facility, University of Edinburgh. We would like to acknowledge the invaluable contributions 737 738 of the research nurses in Orkney, the administrative team in Edinburgh, and the people of 739 Orkney. The CROATIA-Korcula study was funded by grants from the MRC (United 740 Kingdom), European Commission Framework 6 project EUROSPAN (contract number 741 LSHG-CT-2006-018947), Croatian Science Foundation (grant 8875) and the Republic of 742 Croatia Ministry of Science, Education and Sports (216-1080315-0302). Genotyping was 743 performed in the Genetics Core of the Clinical Research Facility, University of Edinburgh. We 744 would like to acknowledge all the staff of several institutions in Croatia that supported the 745 CROATIA-Korcula fieldwork, including, but not limited to, the University of Split and Zagreb 746 Medical Schools, Institute for Anthropological Research in Zagreb, and the Croatian Institute 747 for Public Health in Split. The Viking Health Study-Shetland (VIKING) was supported by the MRC Human Genetics Unit quinquennial programme grant 'QTL in Health and Disease'. DNA 748 749 extractions and genotyping were performed at the Edinburgh Clinical Research Facility. 750 University of Edinburgh. We would like to acknowledge the invaluable contributions of the 751 research nurses in Shetland, the administrative team in Edinburgh and the people of Shetland. 752 We acknowledge support from the European Union's Horizon 2020 research and innovation 753 programme IMforFUTURE (A.L. and A.F.-H.: H2020-MSCA-ITN/721815); the RCUK 754 Innovation Fellowship from the National Productivity Investment Fund (L.K.: MR/R026408/1) 755 and the MRC Human Genetics Unit programme grant, 'QTL in Health and Disease' (J.F.W. 756 and C.H.: MC\_UU\_00007/10). Finally, this research has been conducted using data from the 757 UK Biobank Resource (under application 26041, 48511 and 19655). For the purpose of open 758 access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author 759 Accepted Manuscript version arising from this submission.

- 760
- 761 **Ethics**

All studies were approved by local research ethics committees and all participants have given 762 763 written informed consent. The ORCADES study was approved by the NHS Orkney Research 764 Ethics Committee and the North of Scotland REC. The CROATIA-Korcula study was 765 approved by the Ethics Committee of the Medical School, University of Split (approval ID: 766 2181-198-03-04/10-11-0008). The VIKING study was approved by the South East Scotland 767 Research Ethics Committee, NHS Lothian (reference: 12/SS/0151).

### 769 **Author contributions**

770 A.L.: Data analysis and interpretation, visualisation, writing-original draft preparation, 771 writing—review and editing. P.R.H.J.T.: preparation of pipeline for gene-based aggregation 772 test of rare variants, writing—review and editing, A.F.-H.: computation of new derived IgG 773 glycan traits, data interpretation. I.T.-A.: Quantification of transferrin and IgG N-glycans, 774 computation of derived transferrin glycan traits, writing-review and editing. F.V.: Glycan data quality control. T.P.: Ouantification of transferrin and IgG N-glycans. G.T.: preparation. 775 quality control and annotation of whole-exome sequencing data, writing-review and editing. 776 A.R.S.: Funding. O.P.: Genomic and demographic data provider for CROATIA-Korcula 777 778 cohort. C.H.: Genomic and demographic data provider for CROATIA-Korcula cohort. G.L.: 779 Conceptualisation, glycan data provider, writing-review and editing. J.F.W.: Funding, 780 conceptualisation, genomic and demographic data provider for ORCADES and VIKING 781 cohort, supervision, data interpretation, writing-original draft preparation, writing-review 782 and editing. L.K.: Conceptualisation, supervision, data interpretation, writing—original draft 783 preparation, writing—review and editing.

784

### 785 **Competing interests**

P.R.H.J.T. is an employee of BioAge Labs, Inc. G.T. and A.R.S. are full-time employees of 786 Regeneron Genetics Center and receive salary, stock and stock options as compensation. G.L. 787 788 is the founder and owner of Genos Ltd, a private research organisation that specialises in the 789 high-throughput glycomic analysis and has several patents in this field. A.F.-H., I.T.-A., F.V., and T.P. are employees of Genos Ltd. L.K. is an employee of Humanity Inc., a company 790 791 developing direct-to-consumer measures of biological ageing. All other authors declare no 792 competing interests.